Hansoh Pharma Announces Phase II Clinical Trial Recruitment for HS-10374 in Adults with Moderate-to-Severe Plaque Psoriasis

A Phase II Clinical Study with Multicenter, Randomized, Double-blind, Placebo-controlled Design to Evaluate the Efficacy and Safety of HS-10374 Tablets in Adult Patients with Moderate to Severe Plaque Psoriasis (Protocol Number: HS-10374-201), sponsored by Changzhou Humon Pharmaceutical Co., Ltd., a subsidiary of Hansoh Pharma, has been approved by the National Medical Products Administration (NMPA) and the Ethics Committee of the leading institution. The clinical trial is currently being conducted in multiple hospitals across China, and participants are now being publicly recruited.

Main Inclusion Criteria
1. Male or female, aged 18 to 70 years (inclusive);
2. Diagnosed with plaque psoriasis at least 6 months prior to randomization;
3. As judged by the investigator, eligible for phototherapy or systemic treatment indications;
4. Psoriasis plaque BSA ≥ 10%;
5. PASI score ≥ 12 and sPGA score ≥ 3.

If you are interested in participating in this study, please call the above contact person. A specialist will provide a detailed introduction to the study in person and arrange for you to undergo relevant examinations.

If you meet the requirements, you will receive medication treatment and follow-up observations after the treatment.

Editor: Bai Ji

Disclaimer: The views expressed in this article are solely those of the author and do not represent the position of Pharmcube. We welcome exchanges and additional insights in the comment section; for reprints, please be sure to credit the author and source. If there are any issues regarding the content, copyright, or other aspects of the work, please leave a message on this platform, and we will address it promptly.。